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Abstract
Background: The complexity of schizophrenia lies in the combination of psychiatric, somatic and social needs
requiring care. The aim of the study was to compare perceived needs between groups with absence/presence of
metabolic syndrome (MetS) and to analyze the relationship between needs, health-related quality of life (HRQoL)
and MetS in people with schizophrenia or schizoaffective disorder.
Methods: A “real-world” cross-sectional study was set up with a comprehensive framework including the following,
needs for care (Camberwell Assessment of Need Interview [CAN]), HRQoL (Euro Qol-5D Questionnaire), sociodemographic
data, lifestyle habits, psychopathology (Positive And Negative Syndrome Scale [PANSS]), global functioning (Global
Assessment of Functioning Scale [GAF]), anthropometric measurements and blood test results were assessed for an
outpatient sample (n = 60).
Results: The mean number of needs (given by CAN) was identified for both groups. Patients with MetS rated a higher
number of needs compared to the group without this condition. Mobility problems (given by EQ-5D) were negatively
associated with the number of total and unmet needs. For participants with MetS, HRQoL was related to the number of
needs and unmet needs. For people with MetS, positive symptomatology score (given by PANSS) was related to the
number of needs and met needs and general symptomatology was associated with total, met and unmet needs. For
individuals without MetS, the global functioning score (given by GAF) was significantly inversely related with total, met
and unmet needs.
Conclusions: Needs and HRQoL, as well as general symptomatology, were related only in patients with MetS. This has
implications for treatment planning at the individual and organizational levels. An analysis of both physical and mental
needs could provide a starting point for the extension of facilities in the health care system in order to reach the goal of
improving quality of life.
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Background
The complexity of schizophrenia lies in the combination
of psychiatric, somatic and social needs requiring care
[1, 2]. “Needs for care” has been summarized as “the
requirements of individuals to enable them to achieve,
maintain or restore an acceptable level of social
independence or quality of life (QoL)” [3]. A need is met
when an intervention is efficacious and the patient is
offered effective help; a need is unmet when an interven-
tion has no, or little, effect [4]. The assessment of needs
from a health care service perspective can be beneficial in
the planning and provision of individual care [5]. In
accordance with this idea, Ochoa et al. (on behalf of the
NEDES Group) [6] evaluated outpatients with schizophrenia
using the Camberwell Assessment of Need (CAN). The
most prevalent domains were related to psychotic
symptoms, household skills, need for help with food and
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with information about their condition and treatment.
Zúñiga et al. [7] examined needs in a sample of outpatients
suffering from psychotic and other disorders and found
similar results to those described by Ochoa et al. [6] and
others [8–13]. Factors associated with a higher number of
needs were low socioeconomic class, older age, poorer global
functioning and the presence of psychotic disorder.
Schizophrenia produces a range of disabilities in
everyday life and unmet needs are associated with poor
QoL [6, 13–16]. QoL, a multidimensional construct
that includes subjective well-being and objective mental
and physical function indicators, has been recognized
as an important outcome of schizophrenia treatment
[17, 18]. Health-related quality of life (HRQoL) is re-
stricted to patients’ self-perception of symptomatology,
disability and functional status related to physical and/
or mental health [19].
In this context, the Clinical Antipsychotic Trials of
Intervention Effectiveness Schizophrenia Trial (CATIE)
[20] showed a correlation between schizophrenia, QoL
and the metabolic syndrome (MetS). MetS comprises a
spectrum of medical disorders including abdominal
obesity, insulin resistance, dyslipidemia and elevated
blood pressure and has been associated with an in-
creased risk of developing type 2 diabetes mellitus and
cardiovascular disease. The CATIE study confirmed the
relationship between physical comorbidity and self-
perception of poor physical health, as did the study of
Dixon et al. [21]. A higher functioning score as mea-
sured by the Global Assessment of Functioning (GAF)
scale correlated with a better subjective rating of QoL in
a longitudinal outcome study [22]. Medeiros-Ferreira et
al. [23] studied the relationship between MetS, HRQoL
and global functioning in schizophrenia and schizoaffec-
tive disorder. The prevalence of MetS was 36.8% and
was correlated with higher body mass index (BMI), older
age, unemployment status and better self-care (probably
due to increased awareness of self-image). Patients with
MetS who engaged in physical activity reported a sub-
jective perception of better health and, consequently,
better HRQoL. People with schizophrenia have poorer
access to and quality of health care [24, 25]. It has been
shown that 50 % of individuals with schizophrenia
exhibit at least one physical or other psychiatric
comorbidity [26–28]. Many studies have confirmed the
high prevalence of MetS in schizophrenia in different
contexts, but with very disparate results (11-69 %),
depending on the sample and the methods used [29]. It
is well known that the combination of biological risk,
lifestyle factors and treatment favors the development of
MetS in such patients [23, 28, 30–32]. The importance
of monitoring MetS in people with schizophrenia in
order to reduce the associated risks has been reiterated
by consensus panels throughout the world [31, 33].
While needs can be seen as the starting point for de-
veloping interventions for people with schizophrenia,
the ultimate goal is to improve QoL. The aim of the
present study was therefore to compare needs between
the groups with absence/presence of MetS and to
analyze the relationship between perceived needs for
care, HRQoL, lifestyle habits, psychopathology, global
functioning and MetS in patients with schizophrenia or
schizoaffective disorder in a psychiatric outpatient sam-
ple. We hypothesized that individuals diagnosed with
schizophrenia or schizoaffective disorder and also with
MetS have a higher number of needs and more unmet
needs; poorer HRQoL, lifestyle habits and global func-
tioning and more severe psychopathology than those
without this condition.
Methods
Study design and procedure
This was a “real-world” cross-sectional study. A
“real-world” study is one that is non-interventional
with an unrestricted population, where the basis is
the clinical practice and the focus is the need for
changes in practice. The sample was composed of 60
consecutive patients (23 with MetS and 37 without)
attending the Severe Mental Disorder Program and,
more specifically, the Metabolic Syndrome Protocol at
a public mental health center in Barcelona, Spain.
The inclusion criteria were the following: outpatients
who had received antipsychotic medication for at least
12 weeks, had had a blood test in the previous 3
months and had given informed consent. The exclusion
criterion was incapacity to understand the questions
formulated in Spanish. Those individuals not included
in analysis showed no differences with respect to the
sample subjects in terms of sociodemographic and
clinical characteristics.
Data collection
The interviews were conducted by the patients’ own
psychiatrist (LMF) and reference nurse (RR) in routine
individual sessions (30-45 min) at the mental health cen-
ter. One clinician-investigator (AZL) confirmed the diag-
nosis of schizophrenia or schizoaffective disorder using
the Structured Clinical Interview for DSM-IV Axis I
Disorders (SCID-I) [34] and the other clinician-
investigator (LMF) administered the protocol, ordered
the blood tests and confirmed the diagnosis of MetS
using the modified National Cholesterol Education
Program Adult Treatment Panel Criteria (NCEP-ATP-III
criteria) [35]. The nursing staff (mainly RR) collected all
anthropometric measurements and the perceived needs
(given by CAN) were identified by the social worker (EM).
About 2 months were necessary to collect all information
due to the routine assessment format. The investigators
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were totally familiar with the use of all the chosen in-
struments. The study complied with the principles
contained in the Declaration of Helsinki [36] and was
reviewed and approved by the institutional ethics
board at the study center.
Measurement instruments
All patients were evaluated using the following
instruments:
A sociodemographic and clinical questionnaire that in-
cluded information on psychiatric history, comorbidity,
anthropometric measurements (weight, height, BMI,
waist circumference and blood pressure), metabolic pro-
file (cholesterol, triglycerides and fasting glucose) and
lifestyle (diet, physical exercise, substance use) and anti-
psychotic treatment.
The Positive and Negative Syndrome Scale (PANSS),
Spanish version [37, 38], divided into positive (PANSS-
P), negative (PANSS-N) and general (PANSS-G) symp-
tomatology. The psychometric properties of the PANSS
are currently well documented showing good validity
and reliability with good internal consistency of its five-
factor structure (Cronbach’s alpha >0.70) [37].
The Global Assessment of Functioning (GAF) Scale
[39]. Studies of concurrent validity of the GAF with
schizophrenia samples indicate that the GAF is a valid
measure of global psychological, social, and occupational
functioning [40].
The EuroQol-5 Dimensions (EQ-5D), Spanish version
[41, 42], divided into 2 sections: 1) a descriptive system
that assesses HRQoL in 5 dimensions (mobility, self-
care, usual activities, pain/discomfort, and anxiety/de-
pression), each with 3 levels of severity (value 1 = no
problems, value 2 = some problems, value 3 = severe
problems); 2) a visual analogue scale (VAS) in the form
of a “thermometer” (value 0 = worst and value 100 = best
imaginable health status). It describes the self-perception
of health on each dimension on the day of administra-
tion. In our sample, reliability for the 5 dimensions
evaluated was low (Cronbach’s alpha = 0.664), although it
is mainly due to the reduced number of items not to
inconsistencies of the answers.
The CAN Interview, Spanish version [1, 9, 43], which
evaluates the presence of needs for care in 22 domains
in the previous month. The number of total, met and
unmet needs can be calculated for each domain and re-
corded from different perspectives (service user and/or
staff or caregiver). We considered the patient’s perspec-
tive only. In our sample, Cronbach’s alpha = 0.801 was
obtained.
Data analysis
Statistical analyses were performed using the SPSS 20.0
software package (SPSS Inc., Chicago, Illinois, USA) and
the significance level used was p < 0.05 (2-tailed). The
EQ-5D dimensions were dichotomized into absent/
present (value 1 = absence and value 2 + 3 = presence of
problem) and the number of problems was added up
under the label “EQ-5D Total Score”. The frequency dis-
tributions of met and unmet perceived needs were deter-
mined and the mean number of total, met and unmet
needs was calculated and compared between the groups
with absence/presence of MetS. First, data analyses con-
sisting of the descriptive statistics of all the measure-
ments were done. Subsequently, the Student’s t-test was
used to compare means between continuous variables,
the chi-squared test to study the association between
nominal variables and the Mantel-Haenszel test for
ordinal variables. Pearson correlations were calculated to
measure the degree of association between total, met, un-
met needs and quality of live, psychotic symptomatology.
Given the absence of statistical and clinical differences
between patients with and without MetS (Table 1),
except for the physical measurements which defines
MetS (dyslipidemia, diabetes mellitus), there was no
necessity to statistically adjust for any confounding
variables.
Results
The sociodemographic and clinical characteristics ac-
cording to the absence/presence of MetS in participants
with schizophrenia or schizoaffective disorder are shown
in Table 1. The sample was composed mostly of un-
employed men living with their parents, with a primary
school level of education, who had been diagnosed more
than 15 years earlier, had been treated with more than 2
antipsychotics and had a history of diabetes, cardiovas-
cular disease and dyslipidemia. Most of the participants
were smokers and did not restrict calorie or salt intake,
but were in the habit of eating fibre and engaging in
physical activity. We found that MetS was associated
with a history of cardiovascular disease (p = 0.00), dia-
betes (p = 0.00) and dyslipidemia (p = 0.02).
The percentages of needs in the 22 CAN areas rated by
the patient and their relation to MetS are given in Table 2.
Patients rated a mean of 5.5 total needs (SD = 3.43)
with a score of 4 met (SD = 2.48) and 1.5 unmet needs
(SD = 1.83). Although there were no significant differences
between absence/presence of MetS in the percentages of
needs, we found some high values in some domains. In
the group with MetS, there were 18.1% fewer patients
with no perceived needs in the physical health domain
and 18.7 % fewer patients with met needs in the psychotic
symptoms domain. On the other hand, we found 25.6 %
more patients with met needs in the company domain in
the group without MetS.
As can be seen, in Table 3, there was no association
between the number of needs and the presence of
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Table 1 Sociodemographic and clinical variables according to the absence (N = 37)/presence (N = 23) of metabolic syndrome
MetS No Yes t/Chi2(A) p
Age (mean, SD) 41.7 (10.9) 46.0 (10.1) 1.54 .130
Sex (N = 60) .582 .445
Male 62.2 % 52.2 %
Female 37.8 % 47.8 %
Employment Status (N = 60) .353 .553
Active 18.9 % 13.0 %
Unemployed 81.1 % 87.0 %
Living Arrangements .023 .879
Living with parents 86.5 % 91.3 %
Others 13.5 % 8.7 %
Education (N = 60) .244 .622
Primary school 37.8 % 43.5 %
Secondary school 24.3 % 17.4 %
Medium studies (professional college) 18.9 % 30.4 %
University 18.9 % 8.7 %
Years since diagnosis (N = 59) .570 .450
Less than 5 years 19.4 % 8.7 %
5-10 years 6.0 % 21.7 %
10-15 years 22.2 % 21.7 %
More than 15 years 41.7 % 47.8 %
Lifestyle habits (N = 60)
Smoking 56.8 % 73.9 % 1.79 .180
Alcoholism 24.3 % 26.1 % .024 .878
Abuse of other substances/drugs(B) 29.7 % 17.4 % 1.15 .283
Diet (N = 59)
Unrestricted calories 80.6 % 65.2 % 1.74 .187
Unrestricted salt 66.7 % 56.5 % .618 .432
Unrestricted fibers 66.7 % 65.2 % .013 .909
Unrestricted saturated fat 44.4 % 26.1 % 2.02 .155
Physical activity 69.4 % 65.2 % .115 .735
Medical history (N = 60)
Cardiovascular disease 2.7 % 30.4 % 9.44 .002
Dyslipidemia 8.1 % 30.4 % 5.09 .024
Diabetes mellitus 13.5 % 43.5 % 6.79 .009
Psychopharmacological Treatment (N = 60)
Antipsychotics (AP)- Monotherapy 54.1 % 30.4 % 3.19 .074
Antipsychotics (AP)- Polytherapy 45.9 % 69.6 %
Antidepressants (AD) 40.5 % 39.1 % .012 .914
Anxiolytics/Hypnotics (AN) 59.5 % 69.6 % .624 .430
Mood stabilizers (MS) 32.4 % 43.5 % .745 .388
Others(C) 21.6 % 26.1 % .158 .691
(A): Student’s t for mean comparison; Chi2 for nominal and Mantel-Haenszel for ordinal variables
(B): Caffeine, cannabis, cocaine, hypnotics
(C): Anticholinergics, treatment for alcohol dependence (naltrexone and dissulfiram)
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MetS. The mean number of total needs of the partici-
pants with MetS was 5.95 (SD = 3.97), with a score of
4.26 met (SD = 2.73) and 1.69 unmet needs (SD = 2.20).
The associations between the number of total, met
and unmet needs according to the presence/absence of
MetS and age, EQ-5D total score, EQ-VAS, GAF and
PANSS scores are shown in Table 4. For participants
with MetS, age was associated with the number of needs
(p = 0.463) and unmet needs (p = 0.467). The EQ-5D
total score showed no significant association with MetS.
However, mobility problems (EQ-5D dimension) were
negatively associated with the number of needs (p =
0.01) and unmet (p = 0.03) needs. For people with MetS,
HRQoL was related to the number of needs (p = 0.028)
and unmet (p = 0.043) needs. For patients with MetS,
the PANSS-P score was related to the number of needs
(p = 0.018) and met needs (p = 0.020) and PANSS-G was
associated with the number of needs (p = 0.000), met
Table 2 Percentages (%) of subjects with no needs, met needs or unmet needs for 22 CAN domains (user's perspective) and
stratified by presence/absence of metabolic syndrome
All sample (N = 60) MetS Yes vs Noc
CAN domains No needs (%) Met needs (%) Unmet needs (%) No needs (%) Met needs (%) Unmet needs (%) P
1. Accommodation 95.0 3.3 1.7 -6.0 8.7 -2.7 .691
2. Food 56.7 33.3 10.0 -0.3 2.4 -2.1 .917
3. Looking after the home 45.8 44.1 10.2 -15 2.3 12.8 .120
4. Self-care 86.7 11.7 1.7 0.5 -4.8 4.3 .718
5. Daytime activitiesa 52.5 25.4 22.0 13.7 -13.2 -0.5 .516
6. Physical health 63.3 30.0 6.7 -18.1 7.8 10.3 .084
7. Psychotic symptoms 41.7 55.0 3.3 17.1 -18.7 1.6 .296
8. Informationa 85.0 11.7 1.7 -10.9 9.3 4.3 .844
9. Psychological distress 26.7 41.7 31.7 -8.0 -4.1 12.1 .325
10. Safety to self 85.0 11.7 3.3 3.2 2.2 -5.4 .491
11. Safety to others 88.3 8.3 3.3 4.8 -6.5 1.6 .788
12. Alcohol 95.0 5.0 0.0 1.1 -1.1 0.0 .856
13. Drugs 93.3 5.0 1.7 3.8 -1.1 -2.7 .466
14. Companyb 50.0 23.3 25.0 -17.7 25.6 -12.3 .265
15. Intimate relationshipsb 73.3 21.7 3.3 -13.2 7.2 1.6 .132
16. Sexual expressionb 71.7 15.0 10.0 -10.5 3.9 4.9 .526
17. Child care 96.6 3.4 0.0 5.4 -5.4 0.0 .271
18. Basic education 91.7 6.7 1.7 -0.6 3.3 -2.7 .822
19. Telephone 90.0 8.3 1.7 -4.9 7.6 -2.7 .821
20. Transport 85.0 10.0 5.0 -3.9 -2.1 6.0 .470
21. Money 68.3 23.3 8.3 -19.2 18.6 0.6 .248
22. Welfare benefits 98.3 1.7 0.0 -4.3 4.3 0.0 .205
aN = 59
bUnknown need status was given for each domain due to the user’s refusal to discuss the domain and it was statistically treated as No need (for further details,
please consult www.researchintorecovery.com)
cIndicates the difference for each possible answer (no need, met and unmet need) between patients with and without MetS. For example, for “6.Physical health”,
the value -18.1% indicates that there are18.1% fewer of patients with no needs in the group with MetS than in the group without MetS
Table 3 Comparison of total number of needs, met and unmet
needs according to the absence/presence of metabolic
syndrome
Mean difference
CAN score MetS N Mean of
perceived needs
SD p 95 % CI
Total Needs No 37 5.21 3.12 .425 -2.58 to 1.10
Yes 23 5.95 3.97
Met Needs No 37 3.81 2.36 .503 -1.78 to .885
Yes 23 4.26 2.73
Unmet Needs No 37 1.40 1.58 .556 -1.27 to .691
Yes 23 1.69 2.20
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needs (p = 0.022) and unmet needs (p = 0.001). The
PANSS-N score was not associated with the number of
needs in participants with MetS. For individuals without
MetS, the GAF score was significantly inversely related
to the number of total (p = 0.005), met (p = 0.039) and
unmet needs (p = 0.014).
Discussion
MetS is an important topic for research and clinical
practice in the field of schizophrenia. The same is
true of the study of QoL and needs assessment, both
of which are considered core components of a
community-based mental health treatment program.
Of all the sociodemographic variables analyzed in our
study, age was the only parameter related to needs in
the presence of MetS. The older participants with MetS
identified more total and unmet needs. Meesters et al.
[44] found that elderly people with schizophrenia reported
similar results and they hypothesized that it is probable
that changes associated with aging generate new care
needs and/or modify existing ones. Looking at the data in
detail, we found the higher number of met needs in the
environmental and physical domains. We believe that the
association between age and perceived needs in our
sample can be explained by the effects of a history of
cardiovascular disease, diabetes and dyslipidemia. The as-
sociation between needs and sociodemographic variables
is inconsistent [10, 13, 45].
In our study, we found scores and needs domains
similar to those of other studies [6, 7, 10–12, 45, 46].
Arvidsson [10] found that both staff and patients rated
the most common needs in the domains related to
psychotic symptoms, psychological distress, looking after
the home and company. However, the patients rated a
mean score of total needs that was lower than ours.
McCrone at al. [11] provided further comparisons of
needs in patients with schizophrenia in 5 different
European countries. Despite their specificities, the
between-site differences in overall met needs were very
small, while unmet needs varied substantially. The ma-
jority of the participants from Santander (Spain) were
living with their relatives and accommodation was thus
not a problem; daytime activities, however, were more
frequently reported as a problem than in the other cities.
One of the underlying causes may have been the lack of
alternative structures for day care and psychosocial re-
habilitation. We found that drugs and alcohol in the
CAN interview domains are rarely mentioned as areas of
need due to a possible underreporting of data by the
participants. A description of the most frequently identi-
fied unmet needs can be found in the recent review of
Torres-González et al. [25].
In our study, the individuals with MetS identified more
perceived needs compared to the group without this
condition. However, we found no correlation between
the number of needs and the presence of MetS, probably
due to the strict control of physical health problems by
general practitioners who treat the patients jointly with
mental health professionals. We believe that this com-
prehensive approach minimizes the possible effect of
MetS in the perception of needs for care expressed by
the participants.
HRQoL did not show a significant association with
MetS. However, mobility problems were negatively asso-
ciated with the number of total, met and unmet needs.
While EQ-5D is a generic HRQoL instrument that ex-
plores the perception of health on the day of the inter-
view, CAN explores needs over the previous month and
this may be a reason for this unexpected result. We
came to the conclusion that EQ-5D is probably not
suitable for this kind of study because the influence
of physical and/or mental problems and acute and/or
chronic needs on responses is unclear.
HRQoL was related to the number of total and unmet
needs in participants with MetS. A strong relationship
exists between unmet needs and QoL [13, 14, 45, 47,
48]. Hansson and colleagues [15] found that unmet
needs were associated with poorer QoL and Lambri et
al. [16] found that “the observer-rated psychiatric symp-
tom score did not determine QoL, although self-
reported psychopathology and social need did”. Meesters
et al. [44] found that unmet needs were associated with
poorer QoL in elderly patients with schizophrenia. Al-
though some studies have shown an association between
Table 4 Correlations between the perceived needs and age, health-related quality of life(A), global functioning(B) and symptomatology(C),
stratified by absence/presence of metabolic syndrome
CAN score MetS N AGE EQ-5D total score EQ-VAS GAF PANSS-P PANSS-N PANSS-G
Total Needs No 36 .103 .118 -.200 -.454* .052 .261 .220
Yes 23 .463* .273 -.457* -.260 .490* .220 .680*
Met Needs No 36 .190 .093 -.103 -.346* .069 .172 .092
Yes 23 .296 .292 -.320 -.299 .483* .055 .475*
Unmet Needs No 36 -.080 .102 -.246 -.406* .007 .270 .299*
Yes 23 .467* .129 -.426* -.185 .283 .328 .636*
(A): HRQoL- EQ-5D + EQ-VAS. (B): GAF. (C): PANSS-P + PANSS-N + PANSS-G. *: p < 0.05
Medeiros-Ferreira et al. BMC Psychiatry  (2016) 16:414 Page 6 of 9
schizophrenia and physical problems (including MetS)
and QoL [21, 30, 49, 50], Medeiros-Ferreira et al. [23]
found no correlation between MetS and HRQoL. They
did, however, find that people who engaged in physical
activity reported better self-perceived health and this can
be understood as a feature of HRQoL.
We found that global functioning was significantly re-
lated to needs in participants without MetS. Positive
symptomatology was related to the number of total
and met needs in people with MetS and general
symptomatology was associated with the number of
total needs. This finding might be attributable to the
fact that our study sample consisted of outpatients whose
needs were satisfied by the health care interventions pro-
vided with respect to dealing with positive symptoms but
not with general symptoms (such as anxiety or depres-
sion) associated with perceived needs. Ochoa et al. [6] and
Alvarado et al. [45] found similar results. However, it was
not the aim of these studies to analyze the presence of
MetS and its association with needs and HRQoL.
Our findings should be interpreted with caution. This
was a cross-sectional study and the fact of the possible
overlapping definitions of needs and HRQoL, make it
more difficult to address the differences between the in-
fluence of one or another on the results. Nevertheless,
the association of a higher number of unmet needs with
a lower perception of QoL has emerged as a robust
finding in other studies [16, 44, 48, 50]. Further, it
has not been possible to analyze the sample with
schizophrenia or schizoaffective disorder separately,
the same has occurred with the stratification by typ-
ical or atypical antipsychotics due to the limited num-
ber of patients enrolled in the study. As our sample
was composed of outpatients receiving treatment in a
public mental health center, the results cannot neces-
sarily be generalized to people with other profiles.
The main strength of our study lies in the fact that it
was based on “real-world” clinical practice and exclu-
sively on the participants’ own perceptions of needs. It is
well known that the assessment of needs by patients,
staff and caregivers provides a more comprehensive
evaluation and that mental health interventions must be
chosen based on a negotiation process between them
[10, 44, 51]. Although we totally agree with this per-
spective, we believe that assessing only the perceived
needs and HRQoL of individuals suffering from
schizophrenia or schizoaffective disorder is a way of
empowering them in their own decision-making
process in dealing with the illness. Indeed, in public
health studies the patient’s perspective sheds light on
how people deal with a chronic disease and is given
the same importance as the professional perspective.
In this respect, we disagree with the administration of
the CAN interview only to staff, which is less time-
consuming, but may be not sufficient and appropriate
for clinical routine.
Conclusions
To the best of our knowledge, our study was the first to
analyze the relationship between perceived needs, HRQoL
and MetS in patients with schizophrenia or schizoaffective
disorder. This has implications for treatment planning at
the individual and organizational levels. The future plan is
to develop individualized lifestyle programs for individuals
with this profile based on their specific needs, for example,
changing the control of positive symptomatology as main
focus to a more open perspective that includes interven-
tions in general symptomatology (e.g. somatic concern,
anxiety or poor attention). An analysis of both physical
and mental needs could provide a starting point for the
extension of facilities in the health care system in order to
reach the goal of improving QoL.
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